Tabimorelin
Also known as: NN703
A potent oral GH secretagogue that reached Phase II clinical trials. Though shelved commercially, it remains a testament to oral secretagogue engineering.
Reviewed by Dr. Sarah Mitchell, PharmD, BCPS
Lead Researcher · 12+ years in peptide therapeutics
~2 hours
Research dosing
Oral
Mechanism of Action
Peptide-mimetic that breaches the gastric barrier to activate GHS-R1a receptors and stimulate natural pulsatile GH release from the pituitary.
Key Research Areas
Frequently Asked Questions
What is Tabimorelin?▾
How does Tabimorelin work?▾
What is the recommended dosage for Tabimorelin?▾
What is the half-life of Tabimorelin?▾
Is Tabimorelin FDA approved?▾
Ready to get started with Tabimorelin?
Order from our COA-verified partner — free US shipping, pharmaceutical-grade quality.
Research Disclaimer
The information provided about Tabimorelin is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.